Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 135351

Could increased Pgp-related activity predict outcome in patients undergoing Gleevec therapy?


Svoboda-Beusan, Ivna; Pulanić, Dražen; Sabioncello, Ante; Bulum, Joško; Ajduković, Radmila; Majdak, Patricia; Rabatić, Sabina; Labar, Boris
Could increased Pgp-related activity predict outcome in patients undergoing Gleevec therapy? // The Hematology Journal 4 (S2) / Foa, R ; Goldman, J (ur.).
Rotterdam: Nature Publishing Group, Hampshire, UK, 2003. str. 40-40 (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 135351 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Could increased Pgp-related activity predict outcome in patients undergoing Gleevec therapy?

Autori
Svoboda-Beusan, Ivna ; Pulanić, Dražen ; Sabioncello, Ante ; Bulum, Joško ; Ajduković, Radmila ; Majdak, Patricia ; Rabatić, Sabina ; Labar, Boris

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
The Hematology Journal 4 (S2) / Foa, R ; Goldman, J - Rotterdam : Nature Publishing Group, Hampshire, UK, 2003, 40-40

Skup
8th Annual Congress of the European Hematology Association

Mjesto i datum
Lyon, Francuska, 12-15. 06.2003

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
multidrug resistance; Glivec; CML
(rezistencija na lijekove; Glivec; kronična mijeloidna leukemija)

Sažetak
Background: A1lthough Gleevec (imatinib mesylate) represents successful treatment strategy in chronic myeloid leukemia (CML), some patients are inherently resistant or become resistant during the treatment. In a previous pilot study we monitored long-term follow up, Pgp expression and function in CML patients treated with Gleevec and to estimate the occurrence of multidrug resistance and its correlation to the treatment outcome. Methods: Twenty-four patients aged >22 yrs with advanced CML [4 in blast crisis (BC), 12 in accelerated phase (AP) and 8 in chronic phase (CP)] were monitored in 3 months intervals starting with July 2001. Previous treatment 74 (included HU and IFN alpha ; only 2 patients received MDR-related Ara-C therapy. Gleevec was administered as oral monotherapy: 600 mg daily for BC and AP and 400 mg/day for patients in CP, respectively. The dose was reduced in 11 patients due to toxicity reaction. Bone marrow (BM) and peripheral blood (PB) cells were stained simultaneously with anti HLA-DR/Pgp moAbs and the Pgp phenotype was expressed as the ratio of mean fluorescences (RMF) of specific antibodies and isotype control. Pgp activity was assessed by comparing uptake/efflux rates of Pgp-related Rhodamine dye (Rh123) with Pgp reversing agent, also expressed as RMF. Results: During the therapy eight patients died. In those patients the Rh123 test showed increased activity of Pgp pump in BM and PB. We found lower Pgp activity in 16 responding patients, but after one year follow up study we observed a tendency to Pgp activity increase, which indicates appearance of chemoresistance to further therapy in those patients. Conclusion: Our results indicate the importance of longitudinal follow up of MDR status.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
0021001

Ustanove:
Imunološki zavod d.d.


Citiraj ovu publikaciju:

Svoboda-Beusan, Ivna; Pulanić, Dražen; Sabioncello, Ante; Bulum, Joško; Ajduković, Radmila; Majdak, Patricia; Rabatić, Sabina; Labar, Boris
Could increased Pgp-related activity predict outcome in patients undergoing Gleevec therapy? // The Hematology Journal 4 (S2) / Foa, R ; Goldman, J (ur.).
Rotterdam: Nature Publishing Group, Hampshire, UK, 2003. str. 40-40 (poster, međunarodna recenzija, sažetak, znanstveni)
Svoboda-Beusan, I., Pulanić, D., Sabioncello, A., Bulum, J., Ajduković, R., Majdak, P., Rabatić, S. & Labar, B. (2003) Could increased Pgp-related activity predict outcome in patients undergoing Gleevec therapy?. U: Foa, R. & Goldman, J. (ur.)The Hematology Journal 4 (S2).
@article{article, year = {2003}, pages = {40-40}, keywords = {multidrug resistance, Glivec, CML}, title = {Could increased Pgp-related activity predict outcome in patients undergoing Gleevec therapy?}, keyword = {multidrug resistance, Glivec, CML}, publisher = {Nature Publishing Group, Hampshire, UK}, publisherplace = {Lyon, Francuska} }
@article{article, year = {2003}, pages = {40-40}, keywords = {rezistencija na lijekove, Glivec, kroni\v{c}na mijeloidna leukemija}, title = {Could increased Pgp-related activity predict outcome in patients undergoing Gleevec therapy?}, keyword = {rezistencija na lijekove, Glivec, kroni\v{c}na mijeloidna leukemija}, publisher = {Nature Publishing Group, Hampshire, UK}, publisherplace = {Lyon, Francuska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font